39.59

4.13% 1.57

Monopar Therapeutics Inc (MNPR)

Overview News Price History Financials Discussions Forecast

Monopar Therapeutics Inc stock is traded at $39.59, with a volume of 11,576. It is up +4.13% in the last 24 hours and up +15.66% over the past month. Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Previous Close:

$38.02

Open:

$39.45

24h Volume:

11,576

Relative Volume:

0.24

Market Cap:

$229.16M

Revenue:

Net Income/Loss:

$-7.12M

P/E Ratio:

-17.21

EPS:

-2.3

Net Cash Flow:

$-6.82M

1W Performance:

+24.22%

1M Performance:

+15.66%

6M Performance:

+593.35%

1Y Performance:

+5,944%

1-Day Range:

$38.75

$40.12

1-Week Range:

$32.62

$40.90

52-Week Range:

$0.3438

$54.30

Monopar Therapeutics Inc Stock (MNPR) Company Profile

Name

Monopar Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

(847) 388-0349

Address

1000 SKOKIE BLVD SUITE 350, WILMETTE

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

MNPR's Discussions on Twitter

Compare MNPR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MNPR Monopar Therapeutics Inc	39.59	229.16M	0	-7.12M	-6.82M	-2.30
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-19-25	Resumed	Piper Sandler	Overweight
Jan-10-25	Initiated	Piper Sandler	Overweight
Oct-11-24	Initiated	Rodman & Renshaw	Buy
Jan-28-21	Initiated	ROTH Capital	Buy

Monopar Therapeutics Inc Stock (MNPR) Latest News

Apr 10, 2025

Monopar Therapeutics Inc. acquired worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. for approximately $110 million. - marketscreener.com

Apr 10, 2025

Apr 06, 2025

(MNPR) Long Term Investment Analysis - news.stocktradersdaily.com

Apr 06, 2025

Apr 04, 2025

Major Shareholder Sells Big Chunk of Monopar Therapeutics Stock! - TipRanks

Apr 04, 2025

Monopar Therapeutics CEO Robinson sells $1.17 million in stock By Investing.com - Investing.com Canada

Apr 04, 2025

Jones Trading Reiterates “Hold” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World

Apr 04, 2025

We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth - Yahoo Finance

Apr 02, 2025

Monopar Therapeutics (NASDAQ:MNPR) Receives “Buy” Rating from HC Wainwright - Defense World

Apr 02, 2025

Apr 01, 2025

Top 5 Small-cap Biotech Stocks of 2025 - Nasdaq

Apr 01, 2025

Monopar Therapeutics Stock Hits 52-Week High at $38.91 - MSN

Apr 01, 2025

Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Projections Justify Buy Rating - TipRanks

Apr 01, 2025

Buy Rating for Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Outlook - TipRanks

Apr 01, 2025

Mar 31, 2025

Monopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last year - TipRanks

Mar 31, 2025

Monopar Therapeutics sees cash runway through December 31, 2026 - TipRanks

Mar 31, 2025